Biointron Weekly Reports
News
In our latest episode of the new Antibody ABCs video series, we define single B cell screening . Watch the playlist here.
This Week’s News
Trends – Preventive Measures
The COVID-19 pandemic has reshaped global health strategies, pushing preventive measures to the forefront of public attention.?Now,?there is a renewed focus on fortifying defenses against future viral threats and ways to improve hospitalization rates.?Here, we will?explore the latest?advancements in?post-pandemic prevention strategies and the broader landscape of public health.?
This week, researchers from the University of Colorado Anschutz Medical Campus published a paper in JAMA relating a new machine learning method for allocating scarce COVID-19 monoclonal antibodies during the?pandemic, which could cut hospital cases by a third! Using electronic health record data, machine learning methods, namely policy learning trees, can improve the allocation of scarce therapeutics; therefore, policy learning tree–based allocation should be considered in potential future episodes of therapeutic scarcity, including pandemics.
In the US, COVID-19 has been circulating at higher levels throughout summer, with data from the Centers for Disease Control and Prevention showing that levels of viral activity in wastewater have steadily risen since May. Two newer variants, KP.3.1.1 and KP.2.3, are responsible for over half of all cases.?
Because of these new variants, the FDA is limiting the use of Invivyd ’s COVID-19 pre-exposure prophylactic antibody Pemgarda (pemivibart). They renewed the emergency use authorization last month, but with a notable restriction on its use depending on the prevalence of virus variants.?However, Invivyd also published positive findings from the ongoing Phase III CANOPY study showing an 84% relative risk reduction in symptomatic COVID-19 after prophylaxis with Pemgarda compared with placebo. ?
Also this past week, the The National Institutes of Health has established a pandemic preparedness research network to conduct research on high-priority pathogens most likely to threaten human health with the goal of developing effective vaccines and monoclonal antibodies . They expect to commit $100M per year to fund the program called ReVAMPP.?The?seven participating research centers awarded are: Albert Einstein College of Medicine , RTI International , 美国加州大学尔湾分校 , The University of Texas Medical Branch , 美国华盛顿大学 , Vanderbilt University Medical Center , and Washington University in St. Louis .
Upcoming Events?
In two weeks time, Biointron will be exhibiting at the 22nd Annual Discovery on Target in Boston, MA! Held on September 30 to October 3, 2024, in Sheraton Boston, this four-day event brings back popular topics like kinases, immunomodulation, and degraders, plus new coverage of covalent chemistries and induced proximity, synthetic biology, cancer antibodies, generative AI, and translational models. Meet us at Booth #510 !?
Next month, we will also be exhibiting at BIO Japan 2024 in Yokohama, Japan! The event will be held on October 9-11, 2024,?in?Pacifico Yokohama. Meet us at Booth #D-28 !?
领英推荐
Promotions – 40% OFF Abinvivo Products! ???
Explore Abinvivo, our brand for???????????????????????????? ???? ???????? ????????????????! ?? Save on your project with our ????????-?????????????? ???????????????? - 40% off sitewide!?
Now with online checkout and 1 week delivery:?
?
RushMab - Gene is your go-to solution for quick plasmid production, designed specifically for antibody-related research. We offer a 4-day turnaround, delivering high-quality, transfection-grade expression plasmids for IgG, Fab, VHH, and ScFv sequences. We provide quantities of 100 μg (sufficient for 100 ml culture) with scalability up to grams. Using the reliable pcDNA3.4 backbone, we also accommodate custom vectors. Each plasmid undergoes Sanger sequencing verification and endotoxin control, ensuring precision and safety.
?
New Products & Reports?
Learn more about Biointron at www.biointron.com , or contact us at [email protected] and +1 (732) 790-8340.